Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > LSD-25

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Jan 26, 2022 8:49am

219 Views

Post# 34361496

RE:RE:RE:LSD-25

Correction: 21st century and to add that mankind evolves along with the science except in the case of the COVID-19 pandemic. History will surely record this era being the dumbest of all in pandemic history given what we know (the science) and refuse to do as a global society.

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch